Africa’s biotechnology debate is usually framed as science versus fear. On the ground it is closer to trade versus trust: a question of which markets will buy your grain, and whether your own consumers will eat it. South Africa answered that question decades ago and has been quietly living with the consequences, mostly to its benefit. Several of its neighbours answered the opposite way and have been living with theirs.
South Africa is one of the very few African countries growing genetically modified maize commercially at scale. According to South Africa’s Department of Agriculture, GM maize underpins a meaningful share of its yields and its feed supply. Zambia and Zimbabwe banned it. Now Nigeria and Kenya are moving, and the question is whether the continent is finally taking the South African road.
The Anchor: South Africa’s commercial GM maize
South Africa adopted genetically modified (GM) maize, insect-resistant and herbicide-tolerant varieties, as a mainstream commercial crop, putting it in a small club of African nations doing so at scale. The traits cut crop losses to pests and simplify weed control, which supports the high yields its commercial sector is known for and secures the feed-grain supply its large poultry and livestock industries depend on.
The significance is not just agronomic. It is that South Africa built the regulatory and biosafety machinery to approve, monitor and trade a GM crop, and then operated it for years without the trade collapse or health crisis opponents feared. That track record is itself part of the lead. USDA Foreign Agricultural Service data document South Africa as the continental outlier in biotech maize adoption.
Takeaway: South Africa’s biotech lead is quiet because it is old, the argument was settled in the field years ago.
The Comparators: the bans and the recent shift
Zambia and Zimbabwe took the opposite stance, restricting or banning GM maize, including, at moments of food shortage, refusing GM food aid. The reasons were a mix of consumer and political caution, fear of contaminating non-GM export status, and unresolved regulatory capacity. The result was a hard line that kept the technology out.
The newer development is movement. Nigeria and Kenya have made recent steps toward approving GM crops, signalling a possible thaw in the continent’s resistance. Analysis from AGRA frames this as the central biotech fault line: a continent split between an established adopter, a bloc of refusers, and a group now reconsidering. Whether the recent moves mature into commercial adoption at scale is still open, and the specific approved acreages are best treated as [TK] pending current national data.
Takeaway: the wall around GM maize in Africa is no longer solid, Nigeria and Kenya have started testing the gate.
The Mechanism: regulation, trade and consumer trust
What separates the adopter from the refusers is not the seed, it is the system around it. Commercial GM farming requires a biosafety regulator able to assess and approve traits, a labelling and traceability regime, and export markets that will still buy the grain. Above all it requires enough consumer and political acceptance to make approval survivable.
South Africa built all three. The refusers lacked one or more, often the regulatory capacity and the consumer confidence, and a ban is the simplest response to that gap. This is why the recent Nigerian and Kenyan moves matter: they suggest the regulatory and acceptance machinery is finally being assembled elsewhere.
Takeaway: the barrier to GM maize was never only the science, it was the regulator, the market and the public that had to be ready.
The Verdict: the lead is real, but not a mandate
The honest verdict is that South Africa’s GM lead is a genuine, evidence-backed advantage in yield and feed security, and that the bans carried a real cost in foregone productivity. But it is not a simple instruction for everyone to follow. A country with thin biosafety capacity, GM-sensitive export markets, or strong consumer resistance cannot safely flip a switch, the South African outcome depended on machinery that took years to build and trust that cannot be decreed.
The defensible reading is that GM maize is a tool South Africa has used well, and that the comparators are right to adopt it only once the regulation, traceability and acceptance are in place, which is precisely what the Nigerian and Kenyan steps appear to be building.
The Forward Action: build the biosafety system, then decide
For a policymaker, the action is sequence, not slogan. Build a credible biosafety regulator and a traceability and labelling system before commercialising. Assess which export markets are GM-sensitive and protect them. Invest in transparent public engagement so acceptance is earned, not assumed.
South Africa’s quiet biotech lead is the template, the worked example of GM maize handled with the institutions to match. It is to be emulated where the regulation and trust can be built, adapted where export markets demand caution, and in no case imported as a shortcut. South Africa is the continent’s biotech template; following it responsibly is the choice Nigeria, Kenya and the rest must make on their own terms.
